Global Fund Update. IPC meeting, 11 December 2012

Transcription

1 Global Fund Update IPC meeting, 11 December st MDAG Meeting Geneva June 2012

2 Outline Global Fund Secretariat Procurement Collaboration

3 Grant Management division Grant Management Mark Edington High Impact Africa 1 High Impact Africa 2 High Impact Asia Africa and Middle East AELAC Grant Mgt. Support Michael Byrne Linden Morrison Urban Weber Lelio Marmora Maria Kirova Oren Ginzburg 6 Country Teams 7 Country Teams 7 Country Teams 20 countries comprising 70% of global disease burden Southern & Eastern Africa Cynthia Mwase MENA Joseph Serutoke Western Africa Tina Draser Central Africa Ronald Tran Ba Huy South and East Asia Luca Occhini EEU / CA Nicolas Cantau LAC Silvio Martinelli LFA, Quality, Risk, CCM, Operational Policy and Renewals Technical hubs (procurement, legal, monitoring & program finance) 4 Regions 48 countries 3 Regions 70 countries

4 23 PSM Specialists Embedded in the regional teams Provide recommendations for approval of the PSM plan (or Procurement Plan) and identify solutions towards effective grant implementation. Provide technical guidance on PHPM issues and how to ensure compliance with the Global Fund PSM Policies. Develop recommendations to strengthen systems and capacity in the Pharmaceutical Sector. PSM Hub Operational Policies Technical support Partnership Managing consistency in processes Member of the Operational Risk Management Committee 3. HPM & Health Services Delivery Risks 3.1 Treatment disruptions 3.2 Substandard quality of PHP Poor selection and use of PHP 2 or quality of health services 4

5 Better Grant Management project Risk based Management supported by a ORM Committee Review of the Pharmaceutical Country Profile implementation Strengthened partnership Streamlined the tool (part 2) Reengineering processes Improved procurement planning tool Health product procurement Information system IT tool for PSM plan management, monitoring of procurement activities, and automating VPP process with end activities linked to PQR improve management and oversight of the status of health product procurement and supply at the grant level (active Monitoring) Providing data to forecast demand Market intelligence Initial modules during st MDAG Meeting Geneva June 2012

6 Outline Global Fund Secretariat Procurement Quality Assurance

7 Procurement strategy Strengthen Secretariat s Capacity for strategic market shaping optimize price, quality, design, & sustainable supply 3 additional staff to complement PSS/VPP team Recruitment of Senior Procurement Officer Full staff complement and necessary structure completed by Q Fully implement voluntary pooled procurement (VPP) Improve and reform VPP Mechanism Facilitating Payment options, including allowing for VPP disbursements based on a cost-estimate instead of individual invoices Real time indicative/reference prices from VPP Build previous internal price information sharing Publish quarterly externally: indicative prices/ranges internally: more in-depth analysis/trend information Initially: ARVs, ACTs, LLINs, HIV rapid tests, Malaria rapid tests

8 Strategic Interventions Initial focus 1 st & 2 nd line ARVs New 1 st line ARVs Paed. ARVs

9 Procurement of key products with grant funds From 2009, more than US$ billion 1 of ARVs, long-lasting insecticidal nets, antimalarial and anti-tb medicines were delivered to Principal Recipients and reported to the PQR. Total Product Cost (USD) Product Category Total Product Cost (USD) 2% Bednet $863,800,266 Anti-Retroviral $816,509,939 Anti-Malaria Medicine $145,187,211 Diagnostic test $135,067,022 7% 6% 6% 41% Bednet Anti-Retroviral Anti-Malaria Medicine Diagnostic test Anti-TB Medicine $124,169,159 Condom $37,407,498 38% Anti-TB Medicine Condom Grand Total $2,122,141,095 1 As reported to the PQR on 02 April 2012

10 Global Fund-financed medicines procurement reported in PQR: Purchase orders to date (in million US$) Source: PQR data as at 10 September 2012

11 Procurement since January 2010 as per Global Fund QA Policy First-line TB incl.streptomycin: US$ 53 million Second-line TB: USD 69 million B: SRAauthorized* A: WHOprequalified (including A and B ) Source: PQR data as at 10 Sep 2012

12 Outline Global Fund Secretariat Procurement Quality Assurance

13 Partnerships in Quality Assurance Collaboration with WHO PQ Expert advice QA Policy implementation: ERP management WHO Disease Programs: HIV, Malaria, TB, WHOPES Collaboration/information sharing with other donors and procurement agencies Regular communication with manufacturers Monitoring QA activities and publication of results

14 1. Clinical Criteria 2. Quality Criteria 3. Monitoring Quality Quality monitoring at country level Quality Assurance before arrival of products in country Procurement: Product selection according to Global Fund QA Policy Pre-shipment quality control testing for ERP-reviewed products (organized by Global Fund Secretariat as per QA Policy) Receipt in country, storage, distribution Quality control in countries: Step 1: Selection of quality control laboratory Step2: Designing a sampling and testing programme Step 3: Sampling Step 4: Transport of samples to the laboratory Step 5: Quality control testing results and reports Step 6: Records and documentation Monitoring storage and distribution sites Safe disposal of pharmaceutical products 14

15 Collaboration Collaboration at country and global level: CPP initiative focus on financing flow/situation ACT task force ACT Global Demand Forecast RBM PSM working group National collaboration and coordination: Joint PSM planning, (pharmaceutical country profile) National forecasting and quantification committee Development of procurement plan Harmonize and Streamline supply chain tools, reporting system and data collection Risk assessment and risk mitigation measures Joint action plan for strengthening country systems